Venatorx Pharmaceuticals is headquartered in Malvern, Pennsylvania, USA. The company conducts clinical trials across North America and overseas, including trials involving participants in various EU member states. Venatorx is focused on the discovery and development of novel antiinfectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.
To meet its Article 27 EU Representative obligation, Venatorx appointed The DPO Centre to act as its EU Representation and to review its current processes and procedures for compliance under the GDPR.
Initially, The DPO Centre conducted a high-level compliance review and data mapping exercise. This included reviews of privacy and consent notices and identified which data processors may also process personal data. Venatorx’s Records of Processing Activities (RoPA) was then drafted as required by Article 30 of the GDPR.
The DPO Centre also provided virtual GDPR training for Venatorx employees. This encompassed learning how the GDPR applies to a US-based pharmaceutical company, and what staff should be aware of when handling patient data.
Heather Hunter, Vice President, Communications, Venatorx Pharmaceuticals said: “Venatorx is very pleased with the guidance and support that The DPO Centre has provided us to ensure that we meet the legal requirements of GDPR.
Following the initial data mapping and construction of our RoPA in 2018, we have a good understanding of our processing activities and practical application of the legislation. The DPO Centre recently provided bespoke annual GDPR staff training as part of Venatorx’s ongoing commitment to accountability and compliance. We are confident in the knowledge that our staff understand their responsibilities and The DPO Centre’s team is on hand to assist when required.”
Fill in your details below and we’ll get back to you as soon as possible